NASDAQ:BSTC BioSpecifics Technologies (BSTC) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free BSTC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$88.53▼$88.5350-Day Range$88.22▼$88.5352-Week Range$42.00▼$89.15VolumeN/AAverage Volume61,105 shsMarket Capitalization$650.25 millionP/E Ratio37.51Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BioSpecifics Technologies alerts: Email Address Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> About BioSpecifics Technologies Stock (NASDAQ:BSTC)BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Read More Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> BSTC Stock News HeadlinesMarch 21, 2023 | bizjournals.comSilicon Valley Technology NewsSee More Headlines Receive BSTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2020Today5/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BSTC CUSIP09093110 CIK875622 Webwww.biospecifics.com Phone302-842-8450FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$3.33 Trailing P/E Ratio37.51 Forward P/E Ratio61.91 P/E GrowthN/ANet Income$24.47 million Net Margins47.43% Pretax MarginN/A Return on Equity14.81% Return on Assets14.46% Debt Debt-to-Equity RatioN/A Current Ratio66.24 Quick Ratio66.24 Sales & Book Value Annual Sales$38.19 million Price / Sales17.03 Cash Flow$3.38 per share Price / Cash Flow26.18 Book Value$18.42 per share Price / Book4.81Miscellaneous Outstanding Shares7,345,000Free FloatN/AMarket Cap$650.25 million OptionableNot Optionable Beta0.24 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Ronald Law J.D. (Age 67)Ph.D., Sr. VP of Bus. Devel. Comp: $487.38kMr. Joseph Truitt (Age 55)CEO & Director Mr. Patrick C. Hutchison (Age 61)Chief Financial Officer Mr. Alex MonteithSr. VP & Chief Bus. OfficerCarl A. ValensteinCorp. Sec.Key CompetitorsSinovac BiotechNASDAQ:SVAStemline TherapeuticsNASDAQ:STMLAkouosNASDAQ:AKUSLexicon PharmaceuticalsNASDAQ:LXRXOPKO HealthNASDAQ:OPKView All Competitors BSTC Stock Analysis - Frequently Asked Questions How were BioSpecifics Technologies' earnings last quarter? BioSpecifics Technologies Corp. (NASDAQ:BSTC) posted its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to analysts' expectations of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%. What other stocks do shareholders of BioSpecifics Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). This page (NASDAQ:BSTC) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSpecifics Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.